经腹超声(TAUS)引导近距离放疗治疗宫颈癌的中期结果
研究纳入92例FIGO IB-IVA期宫颈癌患者,2012年2月至2015年6月接受根治性放疗,全盆腔放疗50 Gy/25次、44 Gy后中央遮挡,联合TAUS引导近距离放疗以提升宫颈点总剂量(EQD2)同时保持膀胱和直肠点低剂量。中位随访41.2个月,盆腔控制率84.8%、无病生存率75%、总生存率88%,8例发生2级胃肠道毒性。
要点
- TAUS引导近距离放疗联合全盆腔放疗用于IB-IVA期宫颈癌,中位随访41.2个月盆腔控制率84.8%。
- 无病生存率75%、总生存率88%,8例发生2级胃肠道毒性。
- 宫颈、膀胱、直肠点平均剂量分别为83.5、72.3、76.5 Gy。
核心结论
- 3年结果表明TAUS引导近距离放疗在宫颈癌中可行,并与良好的肿瘤控制和毒性发生率相关。
研究设计与样本
- 单臂研究,纳入92例FIGO IB-IVA期宫颈癌患者,2012年2月至2015年6月接受根治性放疗。
- 全盆腔放疗50 Gy/25次,44 Gy后中央遮挡,联合TAUS引导近距离放疗以提升宫颈点总剂量(EQD2)。
主要发现
- 中位随访41.2个月(范围8至61个月),盆腔控制率84.8%、无病生存率75%、总生存率88%。
- 宫颈、膀胱、直肠点平均剂量分别为83.5、72.3、76.5 Gy。
- 8例患者发生2级胃肠道毒性。
关键数值与推荐
- 全盆腔放疗50 Gy/25次,44 Gy后中央遮挡。
- TAUS引导近距离放疗用于提升宫颈点总剂量(EQD2),同时保持ICRU膀胱和直肠点低剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer. MATERIALS AND METHODS: Ninety-two patients with cervical cancer (stage IB-IVA, according to FIGO staging), were treated by curative radiotherapy from February 2012 to June 2015. All patients were treated with whole pelvic radiotherapy to 50 Gy in 25 fractions and central shielding after 44 Gy, in combination with TAUS-guided brachytherapy, in order to escalate the total dose (EQD2) to the minimal dose at cervical points (in EQD2 concepts) defined by TAUS, while maintaining low doses to ICRU bladder and rectal points. The treatment results and toxicity profiles were reported. RESULTS: At median follow-up time of 41.2 months (range 8 to 61 months) the pelvic control, disease-free survival, and overall survival rates were 84.8%, 75%, and 88%, respectively. The mean applied doses to cervix, bladder, and rectal points were 83.5, 72.3, and 76.5 Gy, respectively. Eight patients developed grade 2 Gastrointestinal toxicity. CONCLUSION: The 3-year results demonstrated that TAUS-guided brachytherapy is feasible and associated with excellent tumor control/toxicity rates in cervical cancer.
引用
- Tharavichitkul E, Chakrabandhu S, Klunklin P, et al. Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer. Gynecol Oncol. 2018. PMID: 29398070. doi:10.1016/j.ygyno.2018.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。